Safety and efficacy of direct-acting antiviral drugs in the treatment of chronic hepatitis C virus infection in patients with thalassemia: a prospective study
Open Access
- 25 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Egyptian Liver Journal
- Vol. 11 (1), 1-6
- https://doi.org/10.1186/s43066-021-00124-5
Abstract
Background Hepatitis C virus (HCV) infection is a major cause of liver-related morbidity and mortality among thalassemic patients. Direct-acting antiviral agents (DAAs) are highly effective and well-tolerated by chronic HCV patients. Results The mean age of our patients was 29 years. Sustained virologic response (SVR) at 12 and 24 weeks was achieved in all patients (100%). The most common side effects were fatigue (18%), anemia (13.63%), and headache (4.5%). There was no statistically significant difference in the hemoglobin level before and after treatment (p = 0.48). There was a significant improvement in serum bilirubin and mean ALT levels after treatment compared to baseline data (p < 0.0005 each). Conclusions DAAs, namely, sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir, are effective and well-tolerated regimens in thalassemic patients with chronic HCV.Keywords
This publication has 18 references indexed in Scilit:
- A national registry of haemoglobinopathies in Greece: Deducted demographics, trends in mortality and affected birthsAnnals of Hematology, 2012
- Safety and Efficacy of Combination Therapy with Pegylated Interferon Alpha-2a and Ribavirin in Treating Patients with Chronic Hepatitis C and Beta-Thalassaemia Major: A Greek Single-Center ExperienceActa Haematologica, 2011
- Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysisJournal of Viral Hepatitis, 2010
- Safety and efficacy of pegylated interferon -2a and ribavirin for the treatment of hepatitis C in patients with thalassemiaHaematologica, 2008
- Treatment of hepatitis C in patients with thalassemiaHaematologica, 2008
- FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotestJournal of Hepatology, 2007
- Seroprevalence of Hepatitis B and Hepatitis C in Patients with Thalassemia and Sickle Cell Anemia in a Long-term Follow-upArchives of Medical Research, 2006
- 585 Peginterferon alpha-2b therapy with and without ribavirin in patients with thalassemia: A randomized studyJournal of Hepatology, 2006
- Efficacy and tolerability of peginterferon alpha‐2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infectionBritish Journal of Haematology, 2005
- Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis CBlood, 2002